Cronos Group Inc. (TSE:CRON – Get Free Report) shares crossed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of C$4.64 and traded as high as C$4.75. Cronos Group shares last traded at C$4.70, with a volume of 216,168 shares traded.
Wall Street Analysts Forecast Growth
Separately, TD boosted their target price on shares of Cronos Group from C$5.50 to C$6.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Three equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of C$4.92.
Get Our Latest Stock Analysis on CRON
Cronos Group Price Performance
The company’s fifty day moving average price is C$4.64 and its 200 day moving average price is C$3.98. The company has a market capitalization of C$1.73 billion, a P/E ratio of 24.74, a PEG ratio of 0.12 and a beta of 1.29. The company has a quick ratio of 24.01, a current ratio of 16.18 and a debt-to-equity ratio of 0.12.
Cronos Group (TSE:CRON – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported C$0.13 earnings per share for the quarter. The company had revenue of C$75.31 million during the quarter. Cronos Group had a net margin of 38.95% and a return on equity of 6.46%. As a group, sell-side analysts forecast that Cronos Group Inc. will post -0.26 EPS for the current year.
Cronos Group Company Profile
Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT and Lord Jones. For more information about Cronos and its brands, please visit: thecronosgroup.com.
Read More
- Five stocks we like better than Cronos Group
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.
